ELV250117P400000
- 29.17
- -1.33-4.36%
Elevance Health Newsroom
Mizuho Securities Maintains Elevance Health(ELV.US) With Buy Rating, Cuts Target Price to $455
Mizuho Adjusts Price Target on Elevance Health to $455 From $505, Keeps Outperform Rating
The Medical assistance program may come under pressure as Morgan Stanley downgrades Elevance Health (ELV.US).
Morgan Stanley Downgrades Elevance Health(ELV.US) to Hold Rating, Cuts Target Price to $388
Morgan Stanley Sticks to Its Buy Rating for Elevance Health (ELV)
Jefferies Maintains Elevance Health(ELV.US) With Buy Rating, Cuts Target Price to $458
Wells Fargo Maintains Elevance Health(ELV.US) With Buy Rating, Cuts Target Price to $483
Wells Fargo Adjusts Price Target on Elevance Health to $483 From $495, Maintains Overweight Rating
Mizuho Securities Maintains Elevance Health(ELV.US) With Buy Rating, Announces Target Price $505
Elevance Health Is Maintained at Overweight by Wells Fargo
Elevance Health Analyst Ratings
Wells Fargo Maintains Elevance Health(ELV.US) With Buy Rating, Cuts Target Price to $495
Elevance Health (ELV) Receives a Buy From Wells Fargo
J.P. Morgan Maintains Elevance Health(ELV.US) With Buy Rating, Cuts Target Price to $548
Deutsche Bank Adjusts Price Target on Elevance Health to $467 From $565
Elevance Health Is Maintained at Overweight by Morgan Stanley
Bernstein Maintains Elevance Health(ELV.US) With Buy Rating, Cuts Target Price to $549
Morgan Stanley Maintains Elevance Health(ELV.US) With Buy Rating, Cuts Target Price to $551
Elevance Health Analyst Ratings
Barclays Maintains Elevance Health(ELV.US) With Buy Rating, Cuts Target Price to $501